Results 81 to 90 of about 1,577 (196)
, 2021 Management for high-risk neuroblastoma (NBL) has included autologous hematopoietic stem cell transplant (HSCT) and anti-GD2 immunotherapy, but survival remains around 50%.
Stephen D. Gilles (11296620) +10 more
core +1 more source
Immunocytokines for cancer treatment: past, present and future [PDF]
Current Opinion in Immunology, 2016 Immunocytokines are antibody-cytokine fusion proteins, with the potential to preferentially localize on tumor lesions and to activate anticancer immunity at the site of disease. Various tumor targets (e.g., cell membrane antigens and extracellular matrix components) and antibody formats (e.g., intact IgG and antibody fragments) have been considered for
Neri, Dario, Sondel, Paul M
openaire +4 more sources
Advanced Science, Volume 12, Issue 34, September 11, 2025.This study combined microscale 3D‐printing with 2D Ti3C2Tx MXene nanosheets to produce electroconductive microfibrous micro‐meshes. By embedding these MXene‐functionalized micro‐meshes within a growth‐supportive macroporous extracellular matrix (ECM)‐based biomaterial, multifunctional biomimetic MXene‐ECM scaffolds were developed.
Ian Woods +10 more
wiley +1 more source
Advanced Science, Volume 12, Issue 31, August 21, 2025.Extracellular matrix remodeling is crucial in cancer progression. Using a peptide to probe the tension of ECM fibers, it was found that Fibronectin fibers gradually lose tension as human breast carcinoma progresses, while their tension is maintained in ductal carcinoma in situ (DCIS), the non‐invasive precursor of breast cancer. This loss of tension is
Arnaud Miéville +6 more
wiley +1 more source
Immunocytokines in cancer treatment: A systematic review
Cancer Treatment ReviewsImmunocytokines are an emerging class of antibody-cytokine fusion proteins combining the specificity of monoclonal antibodies with the potent immunostimulatory effects of cytokines, potentially enhancing the anti-tumor immune response while reducing systemic toxicity.We conducted a systematic review following the PRISMA guidelines.
Agliardi, Stefano +19 more
openaire +2 more sources
Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes
Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 74-79, July 2025.Oncology dose optimization during the era of chemotherapy focused on identifying the maximum tolerated dose (MTD) for registrational trials, often resulting in significant toxicity. The advent of molecular targeted drugs and immunotherapies offers the potential to achieve similar efficacy with lower doses and fewer side effects, as maximal efficacy is ...
Jiawen Zhu +12 more
wiley +1 more source
Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley +1 more source
Cancer‐Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets
MedComm, Volume 6, Issue 7, July 2025.Cancer‐associated fibroblasts (CAFs) arise from normal fibroblasts in response to various tumor microenvironmental signals, including cytokines such as TGF‐β and IL‐6, paracrine factors like PDGFs, Notch signaling, extracellular vesicles, as well as aging, inflammation, hypoxia, oxidative stress, and increased extracellular matrix (ECM) stiffness. Upon
Yutao Li +6 more
wiley +1 more source
Journal of Microbiology, Immunology and Infection, 2020 Background/Purpose: Allergen-specific immunotherapy (SIT) is now considered curative to allergic diseases such as asthma. Mechanistically, our previous work showed DNA hypermethylation of cytokine genes, in T-helper cells, in allergic asthmatic children ...
Chuang-Ming Wang +4 more
doaj +1 more source
Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study
, 2022 e17033 Background: M9241 is an immunocytokine that targets single- and double-stranded DNA which allows the treatment to localize IL-12 to necrotic tumor (Xu, CCR 2017).
Figg, William Douglas +39 more
core +1 more source